רווח נקי למניה (EPS TTM): Forte Biosciences, Inc (FBRX)

Forte Biosciences, Inc. (FBRX) develops skin microbiome correction products targeting pharmacy distribution. On GURU.Markets, the company's annual net profit per share visualizes capital resilience, where -5.10 is the current value of the indicator. High R&D costs and strict FDA oversight limit new entrants. The stability of the US jurisdiction and international conventions protect the research and development base from geopolitical risks.
פילוחים אנליטיים ודוחות נתונים של חברת Forte Biosciences Inc (FBRX)

Trailing twelve-month (TTM) earnings per share measures the actual portion of profit attributable to a single common share, allowing investors to assess capital generation efficiency regardless of the total shares outstanding. By analyzing the company's specific annual income metric, one can diagnose the financial stability of Forte Biosciences, Inc. (FBRX) as it develops an innovative ecosystem for dermatitis therapy and skin barrier restoration.